Insider Transactions in Q1 2026 at Aclaris Therapeutics, Inc. (ACRS)
Insider Transaction List (Q1 2026)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 02
2026
|
James Loerop Chief Business Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,171
-3.83%
|
$12,342
$2.88 P/Share
|
|
Jan 02
2026
|
James Loerop Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
18,150
+10.12%
|
-
|
|
Jan 02
2026
|
Neal Walker CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
9,952
-0.66%
|
$19,904
$2.88 P/Share
|
|
Jan 02
2026
|
Neal Walker CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
29,150
+1.9%
|
-
|
|
Jan 02
2026
|
Kevin Balthaser Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,461
-2.71%
|
$8,922
$2.88 P/Share
|
|
Jan 02
2026
|
Kevin Balthaser Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
13,200
+7.41%
|
-
|
|
Jan 01
2026
|
Kevin Balthaser Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,250
-1.46%
|
$6,750
$3.01 P/Share
|
|
Jan 01
2026
|
Kevin Balthaser Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,500
+4.65%
|
-
|